181 related articles for article (PubMed ID: 16784822)
1. Fra-1 a target for cancer prevention or intervention.
Young MR; Colburn NH
Gene; 2006 Sep; 379():1-11. PubMed ID: 16784822
[TBL] [Abstract][Full Text] [Related]
2. High levels of phosphorylated c-Jun, Fra-1, Fra-2 and ATF-2 proteins correlate with malignant phenotypes in the multistage mouse skin carcinogenesis model.
Zoumpourlis V; Papassava P; Linardopoulos S; Gillespie D; Balmain A; Pintzas A
Oncogene; 2000 Aug; 19(35):4011-21. PubMed ID: 10962557
[TBL] [Abstract][Full Text] [Related]
3. The role of the AP-1 transcription factors c-Fos, FosB, Fra-1 and Fra-2 in the invasion process of mammary carcinomas.
Milde-Langosch K; Röder H; Andritzky B; Aslan B; Hemminger G; Brinkmann A; Bamberger CM; Löning T; Bamberger AM
Breast Cancer Res Treat; 2004 Jul; 86(2):139-52. PubMed ID: 15319566
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide profiling of AP-1-regulated transcription provides insights into the invasiveness of triple-negative breast cancer.
Zhao C; Qiao Y; Jonsson P; Wang J; Xu L; Rouhi P; Sinha I; Cao Y; Williams C; Dahlman-Wright K
Cancer Res; 2014 Jul; 74(14):3983-94. PubMed ID: 24830720
[TBL] [Abstract][Full Text] [Related]
5. Mesothelial cell transformation requires increased AP-1 binding activity and ERK-dependent Fra-1 expression.
Ramos-Nino ME; Timblin CR; Mossman BT
Cancer Res; 2002 Nov; 62(21):6065-9. PubMed ID: 12414630
[TBL] [Abstract][Full Text] [Related]
6. Elevated ERK-MAP kinase activity protects the FOS family member FRA-1 against proteasomal degradation in colon carcinoma cells.
Vial E; Marshall CJ
J Cell Sci; 2003 Dec; 116(Pt 24):4957-63. PubMed ID: 14625389
[TBL] [Abstract][Full Text] [Related]
7. Fos-related antigen 1 modulates malignant features of glioma cells.
Debinski W; Gibo DM
Mol Cancer Res; 2005 Apr; 3(4):237-49. PubMed ID: 15831677
[TBL] [Abstract][Full Text] [Related]
8. AP-1 transrepressing retinoic acid does not deplete coactivators or AP-1 monomers but may target specific Jun or Fos containing dimers.
Suzukawa K; Colburn NH
Oncogene; 2002 Mar; 21(14):2181-90. PubMed ID: 11948401
[TBL] [Abstract][Full Text] [Related]
9. The AP-1 transcription factor FOSL1 causes melanocyte reprogramming and transformation.
Maurus K; Hufnagel A; Geiger F; Graf S; Berking C; Heinemann A; Paschen A; Kneitz S; Stigloher C; Geissinger E; Otto C; Bosserhoff A; Schartl M; Meierjohann S
Oncogene; 2017 Sep; 36(36):5110-5121. PubMed ID: 28481878
[TBL] [Abstract][Full Text] [Related]
10. Fra-1 substitutes for c-Fos in AP-1-mediated signal transduction in retinal apoptosis.
Wenzel A; Iseli HP; Fleischmann A; Hafezi F; Grimm C; Wagner EF; Remé CE
J Neurochem; 2002 Mar; 80(6):1089-94. PubMed ID: 11953459
[TBL] [Abstract][Full Text] [Related]
11. Conversion of HPV 18 positive non-tumorigenic HeLa-fibroblast hybrids to invasive growth involves loss of TNF-alpha mediated repression of viral transcription and modification of the AP-1 transcription complex.
Soto U; Das BC; Lengert M; Finzer P; zur Hausen H; Rösl F
Oncogene; 1999 May; 18(21):3187-98. PubMed ID: 10359524
[TBL] [Abstract][Full Text] [Related]
12. Neoplastic transformation of rat thyroid cells requires the junB and fra-1 gene induction which is dependent on the HMGI-C gene product.
Vallone D; Battista S; Pierantoni GM; Fedele M; Casalino L; Santoro M; Viglietto G; Fusco A; Verde P
EMBO J; 1997 Sep; 16(17):5310-21. PubMed ID: 9311991
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-17 induces AP-1 activity and cellular transformation via upregulation of tumor progression locus 2 activity.
Kim G; Khanal P; Lim SC; Yun HJ; Ahn SG; Ki SH; Choi HS
Carcinogenesis; 2013 Feb; 34(2):341-50. PubMed ID: 23125217
[TBL] [Abstract][Full Text] [Related]
14. Fra-1 negatively regulates lipopolysaccharide-mediated inflammatory responses.
Morishita H; Saito F; Kayama H; Atarashi K; Kuwata H; Yamamoto M; Takeda K
Int Immunol; 2009 Apr; 21(4):457-65. PubMed ID: 19251936
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of Fos-related antigen-1 in head and neck squamous cell carcinoma.
Mangone FR; Brentani MM; Nonogaki S; Begnami MD; Campos AH; Walder F; Carvalho MB; Soares FA; Torloni H; Kowalski LP; Federico MH
Int J Exp Pathol; 2005 Aug; 86(4):205-12. PubMed ID: 16045542
[TBL] [Abstract][Full Text] [Related]
16. Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappaB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes.
Li JJ; Rhim JS; Schlegel R; Vousden KH; Colburn NH
Oncogene; 1998 May; 16(21):2711-21. PubMed ID: 9652737
[TBL] [Abstract][Full Text] [Related]
17. c-Fos is required for TGFbeta1 production and the associated paracrine migratory effects of human colon carcinoma cells.
Liu G; Ding W; Liu X; Mulder KM
Mol Carcinog; 2006 Aug; 45(8):582-93. PubMed ID: 16637060
[TBL] [Abstract][Full Text] [Related]
18. Transition from SCLC to NSCLC phenotype is accompanied by an increased TRE-binding activity and recruitment of specific AP-1 proteins.
Risse-Hackl G; Adamkiewicz J; Wimmel A; Schuermann M
Oncogene; 1998 Jun; 16(23):3057-68. PubMed ID: 9662339
[TBL] [Abstract][Full Text] [Related]
19. FRA-1 expression level modulates regulation of activator protein-1 activity by estradiol in breast cancer cells.
Philips A; Teyssier C; Galtier F; Rivier-Covas C; Rey JM; Rochefort H; Chalbos D
Mol Endocrinol; 1998 Jul; 12(7):973-85. PubMed ID: 9658402
[TBL] [Abstract][Full Text] [Related]
20. Fos family members: regulation, structure and role in oncogenic transformation.
Tulchinsky E
Histol Histopathol; 2000 Jul; 15(3):921-8. PubMed ID: 10963134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
